Paper Details
- Home
- Paper Details
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF<sup>V600</sup> mutant advanced melanoma (INTERIM).
Author: BakerEleanor, BhattacharyyaMadhumita, BoardRuth, BrownCiara O'Hanlon, BrownEwan, BurghelGeorge, CarserJudith, CorriePippa, DansonSarah, DayimuAlimu, DemainLeigh, EcclesBryony, FusiAlberto, GonzalezMichael, GuptaAvinash, HighleyMartin, KumarSatish, MatinRubeta N, MiddletonMark, NobesJenny, PayneMiranda, PickeringLisa, QianWendi, RaoAnkit, StevenNeil, TwelvesSophie, WaterstonAshita, WulffJerome
Original Abstract of the Article :
Label="BACKGROUND" NlmCategory="BACKGROUND">BRAF+MEK inhibitors extend life expectancy of patients with BRAF<sup>V600</sup> mutant advanced melanoma. Acquired resistance limits duration of benefit, but preclinical and case studies suggest intermittent dosing could overcome this limitation. INTERIM w...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1016/j.ejca.2023.113455
データ提供：米国国立医学図書館（NLM）
Intermittent Dabrafenib Plus Trametinib: A New Oasis in the Desert of Melanoma Treatment?
Melanoma, a type of skin cancer, can be a challenging condition to treat. This randomized phase 2 study explores the potential of an intermittent dosing regimen for dabrafenib plus trametinib, two medications commonly used to treat BRAFV600 mutant advanced melanoma. The researchers investigated whether intermittent dosing, as opposed to continuous dosing, could improve treatment outcomes and potentially overcome the limitations of acquired resistance. The findings suggest that intermittent dosing might be a viable strategy for managing melanoma, potentially offering a more sustainable and effective oasis in the desert of treatment options.
Exploring New Paths: Navigating the Desert of Melanoma Treatment
This study highlights the ongoing search for innovative and effective strategies to manage melanoma. The exploration of intermittent dosing for dabrafenib plus trametinib offers a potential oasis in the desert of treatment options, potentially providing a more sustainable and effective approach to managing this challenging condition.
A Potential Oasis for Personalized Treatment: Finding the Right Path in the Desert of Melanoma Care
If you're facing melanoma, it's crucial to discuss all available treatment options with your healthcare provider. This research suggests that intermittent dosing could be a valuable strategy for managing melanoma, offering a potential oasis in the desert of treatment choices. Finding the right path through this challenging terrain requires a collaborative approach between patient and healthcare professional, ensuring the best possible outcome.
Dr. Camel's Conclusion
This study delves into the potential of intermittent dosing for dabrafenib plus trametinib in melanoma treatment, offering a potential oasis in the desert of treatment options. The research underscores the importance of exploring new strategies to overcome the challenges of acquired resistance and improve patient outcomes. Like a skilled desert traveler, we must be adaptable and resourceful in finding the right path to recovery.
Date :
- Date Completed n.d.
- Date Revised 2023-11-29
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.